Key terms
About DMAC
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DMAC news
Mar 21
4:49pm ET
DiaMedica Therapeutics files $100M mixed securities shelf
Mar 21
9:13am ET
DiaMedica Therapeutics price target lowered to $8 from $11 at Craig-Hallum
Mar 21
9:00am ET
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)
Mar 21
7:38am ET
DiaMedica Therapeutics price target lowered to $6 from $7 at Oppenheimer
Mar 20
8:50am ET
Analysts Conflicted on These Healthcare Names: Diamedica Therapeutics (DMAC), Design Therapeutics (DSGN) and MiMedx Group (MDXG)
Mar 05
8:48am ET
Craig-Hallum Sticks to Their Buy Rating for Diamedica Therapeutics (DMAC)
Jan 22
8:25am ET
DiaMedica Therapeutics names Lorianne Masuoka chief medical officer
No recent news articles are available for DMAC
DMAC Financials
Key terms
Ad Feedback
DMAC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DMAC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
